Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...
For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...
Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Closely-held Seamless will design a type of enzyme ...
Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the recent quarter. Eli Lilly (NYSE: LLY) has behaved more like a tech stock in ...
Evangeline Lilly is opening up about her costly treatment following a traumatic brain injury. “I have spent a lot of money getting evaluated and getting targeted, expert advice on how to heal my brain ...
Evangeline Lily gave an update on her treatment plan after suffering a traumatic brain injury. The “Lost” star, 46, took to Instagram on Sunday, sharing how she was “restor[ing her] brain health.” “I ...
Eli Lilly (LLY 1.51%) has behaved more like a tech stock in recent years than like a pharma stock. Tech players are known to soar in the double and triple digits when the environment and corporate ...
Evangeline Lilly Says She Has 'Spent a Lot of Money' to Find a 'Remedy' After Traumatic Brain Injury
The actress revealed her supplements in an Instagram video on Sunday, Jan. 25 Evangeline Lilly/Instagram Evangeline Lilly revealed she’s spent a large amount of money trying to find the right remedy ...
Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Pennsylvania's Lehigh Valley that will help make its next-generation obesity drugs. That includes a closely watched ...
Drug giant Eli Lilly LLY3.66%increase; green up pointing triangle said it plans to open a $3.5 billion plant in Pennsylvania’s Lehigh Valley, giving the region an economic shot in the arm and helping ...
Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company's leading position is already being tested by Novo Nordisk's GLP-1 weight loss pill. Merck and Bristol Myers Squibb have ...
Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results